Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

________________

 

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER

 

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

November 26, 2021

________________

 

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

 

 

Novo Allé 

DK- 2880, Bagsvaerd 

Denmark

(Address of principal executive offices)

________________

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

 

Form 20-F [X]

Form 40-F [  ]

 

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes [  ]

No [X]

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________

 

 

 

 

 

 

 

Novo Nordisk announces impact from Volume Based Procurement for insulin in China

 

Bagsværd, Denmark, 26 November 2021 – Novo Nordisk today announced that the company has received the results from the Volume Based Procurement (VBP) tender for insulin in China. The Chinese National Healthcare Security Administration has tendered insulin sold at hospitals, and Novo Nordisk has participated in the tender. All Novo Nordisk’s insulin were included in the tender except for Ryzodeg® and Xultophy®.

 

Novo Nordisk currently expects an estimated negative impact on global sales growth of around 3% in 2022 as a result of reduced prices and reduced volumes of insulin sold in China. The VBP for insulin is expected to be implemented during the first half of 2022.

 

Novo Nordisk will provide the financial outlook for 2022 in connection with the announcement of the full-year 2021 results on 2 February 2022. 

 

 

About Novo Nordisk

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).  

 

 

Page 2 of 2

Further information

 

Media:
Mette Kruse Danielsen	[phone]	[e-mail]
Michael Bachner (US)	[phone]	[e-mail]
Investors:
Daniel Muusmann Bohsen	[phone]	[e-mail]
Ann Søndermølle Rendbæk	[phone]	[e-mail]
David Heiberg Landsted	[phone]	[e-mail]
Mark Joseph Root (US)	[phone]	[e-mail]

 

 

Novo Nordisk A/S Investor Relations	Novo Allé 2880 Bagsværd Denmark	Telephone: [phone]	Internet: www.novonordisk.com CVR no: 24 25 67 90
		Company announcement No 74/ 2021

 

 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

 

Date: November 26, 2021

NOVO NORDISK A/S   Lars Fruergaard Jørgensen Chief Executive Officer